CSL Ltd (ASX: CSL)
According to a note out of Goldman Sachs, its analysts have retained their buy rating on this biotechnology giant's shares with a trimmed price target of $318.40. Goldman felt that CSL delivered a mixed half year result last week. The broker points out that strong immunoglobulin growth and solid gross margin improvements in the CSL Behring business were overshadowed by a weaker than expected performance from its Seqirus influenza vaccines segment. However, given the importance of the CSL Behring business, Goldman believes investors should be focusing more on its improvements. In addition, it is confident that the company will deliver on its annual double-digit earnings growth target this year and over the medium term. The CSL share price ended the week at $256.90.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$239.10 |
Change
0.240(0.10%) |
Mkt cap ! $115.7B | |||
| Open | High | Low | Value | Volume |
| $238.23 | $241.14 | $238.23 | $90.14M | 376.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 554 | $238.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $239.10 | 1999 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CSL (ASX) Chart |